Guideline
Members are eligible for GEP testing as follows:
I.
Advanced cancer; next generation sequencing (NGS), when performed with a diagnostic lab test that has received FDA approval or clearance (e.g., Foundation One CDx) Covered for Medicare members only when the following criteria are met: 1. Member has i. either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; and ii. either not been previously tested using the same NGS test for the same primary diagnosis of cancer or repeat testing using the same NGS test only when a new primary cancer diagnosis is made by the treating physician; and iii. decided to seek further cancer treatment (e.g., therapeutic chemotherapy) 2. The diagnostic laboratory test using NGS must have:
i. FDA approval or clearance as a companion in vitro diagnostic; and ii. an FDA approved or cleared indication for use in that patient's cancer; and iii. results provided to the treating physician for management of the patient using a report template to specify treatment options 
II.

